Dexcel Pharma has a wide range of products (in a variety of doses) under development and numerous generic products under submission. Dozens of bio-equivalence studies are planned annually, with a substantial number of new product dosages to be launched by 2017.

Innovative Product Pipeline

Dexcel Pharma also has several innovative products under development, for the treatment of gastroenterological, cardiovascular and central nervous system diseases.